加载中
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
收盘时
US$95.84
−US$1.12 · -1.16%
盘后
US$96.02
+US$0.18 · +0.19%
10月12日 19:57 ET
盘中时间采用ET。市场数据可能有所延迟。
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
日内区间
当前US$95.84
52周区间
当前US$95.84
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
49
合理估值
情绪
66
看涨
风险
41
风险偏高
动量
38
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
日内区间
当前US$95.84
52周区间
当前US$95.84
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 27.57亿 EUR | 27.51亿 EUR | 38.19亿 EUR | 173.11亿 EUR | 189.77亿 EUR |
| 销货成本 | 6.16亿 EUR | 5.41亿 EUR | 6亿 EUR | 29.95亿 EUR | 29.12亿 EUR |
| 毛利 | 21.4亿 EUR | 22.1亿 EUR | 32.19亿 EUR | 143.16亿 EUR | 160.65亿 EUR |
| 研究与开发 | 20.22亿 EUR | 22.54亿 EUR | 17.83亿 EUR | 15.37亿 EUR | 9.49亿 EUR |
| 销售、一般及管理费用 | 6.98亿 EUR | 5.99亿 EUR | 5.58亿 EUR | 5.41亿 EUR | 3.27亿 EUR |
| 营业费用 | 27.64亿 EUR | 35.24亿 EUR | 25.29亿 EUR | 16.73亿 EUR | 7.81亿 EUR |
| 利息收入 | 2.52亿 EUR | — | 3.51亿 EUR | 4736.7万 EUR | 156.37万 EUR |
| 利息支出 | 1363.96万 EUR | 1316.18万 EUR | 776.1万 EUR | 1582.15万 EUR | 562.93万 EUR |
| 折旧和摊销 | 3.68亿 EUR | 2.98亿 EUR | 1.83亿 EUR | 1.23亿 EUR | 7520万 EUR |
| 营业利润 | −6.24亿 EUR | −13.14亿 EUR | 6.9亿 EUR | 126.43亿 EUR | 152.84亿 EUR |
| 净利润 | −10.91亿 EUR | −6.65亿 EUR | 9.3亿 EUR | 94.34亿 EUR | 102.93亿 EUR |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$121
上涨空间 26.25%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2022年6月2日 | US$2.111Irregular | 2022年6月3日 | 2022年6月17日 |
除息 2022年6月2日
US$2.111
Irregular
2022年6月3日登记 · 支付日 2022年6月17日
报告持有此股票敞口的交易所交易基金。
First Trust NYSE Arca Biotechnology Index FundFBT9594.97万3.32%28.91亿 USD0.55%US$263.9-0.57%
iShares Biotechnology ETFIBB7206.35万0.66%108.2亿 USD0.44%US$204.26-1.08%
Schwab Fundamental International Large Company Index ETFFNDF1569.32万0.06%253.2亿 USD0.25%US$53.42-0.35%
iShares Genomics Immunology and Healthcare ETFIDNA980.75万3.07%3.15亿 USD0.47%US$41.56-1.45%
State Street SPDR Portfolio Developed World ex-US ETFSPDW946.16万0.02%404.62亿 USD0.03%US$49.69-0.58%
VanEck Biotech ETFBBH771.41万1.59%4.85亿 USD0.35%US$239.22-0.38%
JPMorgan BetaBuilders Europe ETFBBEU708.06万0.08%88.29亿 USD0.09%US$74.69-0.44%
Invesco NASDAQ Next Gen 100 ETFQQQJ666.64万0.56%12亿 USD0.15%US$44.59-0.82%First Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab Fundamental International Large Company Index ETFFNDFiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Biotech ETFBBHJPMorgan BetaBuilders Europe ETFBBEUInvesco NASDAQ Next Gen 100 ETFQQQJAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
